Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.52 |
| ▸ | NQO2 | P16083 | 4/20 | 0.51 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.50 |
| ▸ | GPR183 | P32249 | 1/20 | 0.49 |
| ▸ | ADGRF1 | Q5T601 | 1/20 | 0.49 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1842659 | 1.00 | SIRT1 (0.56) | SIRT1MTNR1BMTNR1ANQO2C5AR1 | |
| SCHEMBL30695338 | 1.00 | SIRT1 (0.56) | SIRT1MTNR1BMTNR1ANQO2C5AR1 | |
| SCHEMBL1844201 | 1.00 | SIRT1 (0.56) | SIRT1MTNR1BMTNR1ANQO2C5AR1 | |
| Hydrochloric Acid SCHEMBL1846869 | 0.99 | SIRT1 (0.55) | SIRT1MTNR1BMTNR1ANQO2C5AR1 | |
| SCHEMBL30746730 | 0.91 | MTNR1A (0.56) | MTNR1BMTNR1ANQO2 | |
| SCHEMBL1842495 | 0.91 | MTNR1A (0.56) | MTNR1BMTNR1ANQO2 | |
| Hydrochloric Acid SCHEMBL9628615 | 0.90 | MTNR1A (0.54) | MTNR1BMTNR1ANQO2 | |
| SCHEMBL1844672 | 0.88 | SIRT1 (0.53) | SIRT1 | |
| SCHEMBL5847603 | 0.87 | MTNR1A (0.54) | MTNR1BMTNR1ANQO2C5AR1GPR183 | |
| SCHEMBL3714922 | 0.87 | MTNR1B (0.52) | MTNR1BMTNR1ANQO2C5AR1GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| US-6911543-B2 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PFIZER INC. (US) | 2005-06-28 | — | — | US | claimed |
| WO-2017123518-A1 | AMINOTRIAZOLE IMMUNOMODULATORS FOR TREATING AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017123518-A1 | AMINOTRIAZOLE IMMUNOMODULATORS FOR TREATING AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2017-07-20 | — | — | WO | disclosed |
| EP-1318140-B9 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-05-21 | — | — | EP | disclosed |
| US-8198454-B2 | Amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| US-8071810-B2 | 3-(3-Amino-2,6-diisopropyl-phenyl)-1-(4-isopropyl-phenyl)-1-(4-methoxy-benzyl)-urea; autoimmune disorders; inflammation | JERINI AG (DE) | 2011-12-06 | — | — | US | disclosed |
| EP-1318140-B1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-7855297-B2 | Amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20100041656-A1 | Novel amide derivatives and medicinal use thereof | NAKAMURA MITSUBARU | 2010-02-18 | — | — | US | disclosed |
| US-20080220003-A1 | C5a Receptor Antagonists | JERINI AG (DE) | 2008-09-11 | — | — | US | disclosed |
| EP-1318140-A1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF UGS | Mitsubishi Pharma Corporation (JP) | 2003-06-11 | — | — | EP | disclosed |
| US-6576657-B2 | Nitrogen containing heterocyclic compounds useful as anticoagulants | ASTRAZENECA AB (SE) | 2003-06-10 | — | — | US | disclosed |
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2002-02-21 | — | — | US | disclosed |
| US-6265397-B1 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2001-07-24 | — | — | US | disclosed |
| EP-1012140-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998057932-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-12-23 | — | — | WO | disclosed |
| US-4898876-A | Benzoylpiperazine esters and a process for their production | KOWA CO., LTD. (JP) | 1990-02-06 | — | — | US | disclosed |
| EP-0098713-A2 | Benzoylpiperazine esters and a process for their production | KOWA COMPANY, LTD. (JP) | 1984-01-18 | — | — | EP | disclosed |
| EP-0071433-A1 | Medicine for the treatment of diabetes | KOWA COMPANY, LTD. (JP) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | SIRT1 4210/4885MTNR1B 285/4885MTNR1A 506/4885 |
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, SERPINB1 | SIRT1 1566/4885MTNR1B 794/4885MTNR1A 1135/4885 |
| US-20100041656-A1 | Novel amide derivatives and medicinal use thereof | C5AR1, C5AR2, C3AR1 | SIRT1 565/4885MTNR1B 1428/4885MTNR1A 1044/4885 |
| US-20080220003-A1 | C5a Receptor Antagonists | C3AR1, C5AR2, C5AR1 | SIRT1 3929/4885MTNR1B 517/4885MTNR1A 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.